Form 4: Revelation Biosciences Director Acquires Shares in Recent Transaction

Director Lakhmir S Chawla reports acquisition of Revelation Biosciences shares on February 11, 2025.

Summary

• On February 11, 2025, Lakhmir S Chawla, a director of Revelation Biosciences, acquired 181 shares of common stock at a price of $3.87 per share.
• Following the transaction, Mr. Chawla directly owns 181 shares of Revelation Biosciences.
• The shares were acquired through a restricted stock grant under the 2021 Equity Incentive Plan, vesting 100% on the grant date.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a stock transaction by a company director. While insider buying can be seen as a positive signal, the small number of shares acquired doesn't strongly indicate a major shift in sentiment.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is a routine part of corporate governance and transparency, providing insight into the transactions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholders if it signals confidence from a company director.

Key Dates

Keywords

Revelation Biosciences, REVB, Lakhmir S Chawla, Director, Stock Acquisition, Form 4, Equity Incentive Plan, Beneficial Ownership